Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3A | P31941 | 1/20 | 0.59 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.59 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.57 |
| ▸ | FBP1 | P09467 | 2/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.44 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.41 |
| ▸ | RELA | Q04206 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3090628 | 0.98 | PDK1 (0.56) | APOBEC3AAPOBEC3GPDK1FBP1ADRA2A | |
| SCHEMBL2147098 | 0.93 | — | — | |
| SCHEMBL7325816 | 0.78 | APOBEC3A (0.61) | APOBEC3AAPOBEC3GPDK1FBP1ADRA2A | |
| SCHEMBL10965367 | 0.76 | APOBEC3A (0.59) | APOBEC3AAPOBEC3GPDK1FBP1ADRA2A | |
| SCHEMBL24869474 | 0.74 | APOBEC3A (0.57) | APOBEC3AAPOBEC3GPDK1FBP1ADRA2A | |
| SCHEMBL12344114 | 0.74 | APOBEC3A (0.57) | APOBEC3AAPOBEC3GPDK1FBP1ADRA2A | |
| SCHEMBL23571354 | 0.74 | APOBEC3A (0.57) | APOBEC3AAPOBEC3GPDK1FBP1ADRA2A | |
| SCHEMBL2747663 | 0.74 | APOBEC3A (0.57) | APOBEC3AAPOBEC3GPDK1FBP1ADRA2A | |
| SCHEMBL23666043 | 0.74 | APOBEC3A (1.00) | APOBEC3AAPOBEC3GPDK1FBP1ADRA2A | |
| SCHEMBL1670074 | 0.74 | APOBEC3A (1.00) | APOBEC3AAPOBEC3GPDK1FBP1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3107901-B1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | PIRAMAL ENTPR LTD (IN) | 2020-04-01 | — | — | EP | disclosed |
| US-10227360-B2 | Compounds for use as GPR120 agonists | Piramal Enterprises Limited (IN) | 2019-03-12 | — | — | US | disclosed |
| EP-3107901-A1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | Piramal Enterprises Limited (IN) | 2016-12-28 | — | — | EP | disclosed |
| US-20160347768-A1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | Piramal Enterprises Limited (IN) | 2016-12-01 | — | — | US | disclosed |
| WO-2015125085-A1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | Piramal Enterprises Limited (IN) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227360-B2 | Compounds for use as GPR120 agonists | GPR119, GPR55, GPR180 | APOBEC3A 4762/4885APOBEC3G 4640/4885PDK1 3266/4885 |
| US-20160347768-A1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | GPR119, GPR55, GPR180 | APOBEC3A 4762/4885APOBEC3G 4640/4885PDK1 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.